Alzheimer’s Disease CSF Biomarker Profiles in Idiopathic Normal Pressure Hydrocephalus

Salvatore Mazzeo 1,2, Filippo Emiliani 1, Silvia Bagnoli 1, Sonia Padiglioni 3,4, Lorenzo Maria Del Re 5, Giulia Giacomucci 1,4, Juri Balestrini 1, Assunta Ingannato 1, Valentina Moschini 6, Carmen Morinelli 6, Giulia Galdo 1, Cristina Polito 2, Camilla Ferrari 1, Gastone Pansini 7, Alessandro Della Puppa 1, Sandro Sorbi 1,2, Benedetta Nacmias 1,2, 6 and Valentina Bessi 1,4,*

1 Department of Neuroscience, Psychology, Drug Research and Child Health, Careggi University Hospital, University of Florence, Largo Brambilla, 3, 50134 Florence, Italy; salvatore.mazzeo@unifi.it (S.M.); filippo.emiliani@unifi.it (F.E.); silvia.bagnoli@unifi.it (S.B.); giuliagiacomucci.md@gmail.com (G.G.); juri.balestrini@unifi.it (J.B.); assunta.ingannato@unifi.it (A.I.); giulia.galdo@unifi.it (G.G.); camilla.ferrari@unifi.it (C.F.); alessandro.dellapuppa@unifi.it (A.D.P.); sandro.sorbi@unifi.it (S.S.); benedetta.nacmias@unifi.it (B.N.)
2 IRCCS Fondazione Don Carlo Gnocchi, 50143 Florence, Italy; cristina.polito@unifi.it
3 Regional Referral Centre for Relation Criticalities, 50139 Florence, Italy; sonia_padiglioni@libero.it
4 Research and Innovation Centre for Dementia-CRIDEM, Careggi University Hospital, 50134 Florence, Italy
5 Research Unit of Medicine Ageing, Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy; lorenzomaria.delre@unifi.it
6 Dipartimento Neuromososuco-Scheletroco e Degli Organi di Senso, Careggi University Hospital, 50134 Florence, Italy; valentina.moschini02@gmail.com (V.M.); carmen.morinelli@studenti.unipd.it (C.M.)
7 Neurosurgery Unit, Careggi University Hospital, Largo Giovanni Alessandro Brambilla 3, 50134 Florence, Italy; gastonepansini@gmail.com

* Correspondence: valentina.bessi@unifi.it; Tel.: +39-05-7948660; Fax: +39-05-7947484

Abstract: Patients with idiopathic normal pressure hydrocephalus (iNPH) frequently show pathologic CSF Aβ42 levels, comparable with Alzheimer’s Disease (AD). Nevertheless, the clinical meaning of these findings has not been fully explained. We aimed to assess the role of AD CSF biomarkers (Aβ42, Aβ40/Aβ42, p-tau, t-tau) in iNPH. To this purpose, we enrolled 44 patients diagnosed with iNPH and 101 with AD. All the patients underwent CSF sampling. We compared CSF biomarker levels in iNPH and AD: Aβ42 levels were not different between iNPH and AD, while Aβ42/Aβ40, p-tau, and t-tau were significantly different and showed excellent accuracy in distinguishing iNPH and AD. A multiple logistic regression analysis showed that Aβ42/Aβ40 was the variable that most contributed to differentiating the two groups. Furthermore, iNPH patients with positive Aβ42/Aβ40 had higher p-tau and t-tau than iNPH patients with negative Aβ42/Aβ40. Those iNPH patients who showed cognitive impairment had lower Aβ42/Aβ40 and higher p-tau than patients without cognitive impairment. We concluded that positive CSF Aβ42 with negative Aβ42/Aβ40, p-tau, and t-tau is a typical CSF profile of iNPH. On the contrary, positive Aβ42/Aβ40 in iNPH patients, especially when associated with positive p-tau, may lead to suspicion of a coexistent AD pathology.

Keywords: Alzheimer’s Disease; idiopathic normal pressure hydrocephalus; cerebrospinal fluid; biomarkers; cognitive impairment

1. Introduction

Idiopathic normal pressure hydrocephalus (iNPH) is the most common form of hydrocephalus in adults with an estimated prevalence of 5.9% in patients over 80 years [1]. It is characterized by a classical triad of symptoms (cognitive disturbances, balance/gait impairment, and urinary incontinence), in the presence of a communicating hydrocephalus and a normal opening pressure upon lumbar puncture [2]. It is crucial to diagnose this condition early because 70–80% of patients show clinical improvement following ventriculoperitoneal shunt insertion [3]. Nevertheless, iNPH diagnosis could be challenging because...
the typical clinical triad is neither sensitive (it is present in <60% of patients [4,5]), nor specific, as clinical features of iNPH are shared with other cognitive and movement disorders, such as Alzheimer’s Disease (AD), vascular dementia, Parkinson’s disease, and atypical parkinsonian syndromes [6–9]. Moreover, cerebrospinal fluid (CSF) concentration of Aβ42 (one of the AD core biomarkers, whose reduction reflects Aβ amyloid plaques deposition in the brain [10]) was widely shown to be reduced also in iNPH [11]. In iNPH, the reduction of Aβ42 seems not to be related to Aβ amyloid plaques deposition, but to downregulation of Aβ production due to periventricular hypometabolism [12] and to the impairment of glymphatic clearance mechanisms and CSF turnover [13,14].

However, concomitant AD neuropathologic changes have been frequently seen in brain biopsies or in postmortem neuropathological examinations of patients with clinical diagnoses of iNPH [15–17]. Furthermore, the presence of AD pathology in iNPH was found to be associated with neuropsychiatric symptoms and behavior changes [18–21], as well as response to ventricular-peritoneal shunt [22–26]. Due to this evidence, a CSF AD biomarker analysis may have diagnostic and prognostic value, influencing the management of iNPH patients.

Nevertheless, CSF Aβ42 measurement is influenced by interindividual physiological differences in amyloid processing [27] and false negatives are common also in patients with AD, as well as false positives in patients with other neurogenerative diseases and healthy individuals [28]. Measurement of the Aβ40 and Aβ42/Aβ40 ratio have been proposed to overcome this limit [28]. Aβ40 is the most abundant Aβ peptide and is less likely to aggregate than Aβ42. In AD, the reduced levels of Aβ42 are associated with slightly increased or steady levels of Aβ40 [29]. Therefore, the Aβ42/Aβ40 ratio is lower in AD than in healthy controls and showed higher accuracy as compared to Aβ42 in distinguishing AD from other neurodegenerative diseases [28]. In contrast, in iNPH patients, the CSF levels of all the amyloid precursor protein (APP) fragments (Aβ38, Aβ40, Aβ42, sAPPα, and sAPPβ) are decreased compared to controls [11,12,30]. Hence, we speculated that while Aβ42 levels are reduced in the CSF of iNPH patients, Aβ42/Aβ40 may be normal and could be the key factor in interpreting results of CSF biomarkers in iNPH. In this study, we aimed to test our hypothesis by assessing the accuracy of each CSF biomarker in distinguishing iNPH and AD patients to define a typical biomarker profile of iNPH.

2. Materials and Methods
2.1. Participants and Clinical Assessment

We included 44 patients diagnosed with iNPH according to international guidelines [7] and 101 patients diagnosed with AD according to NIA-AA criteria [31]. All of the patients were consecutively referred to the Centre for Alzheimer’s Disease and Adult Cognitive Disorders and Neurology Unit of Careggi Hospital in Florence for CSF collection between December 2018 and March 2022.

All patients in the iNPH group had ventricular enlargement associated with a patent Sylvian aqueduct and the absence of a macroscopic obstruction of CSF flow, lack of cortical atrophy, presence of periventricular water content, and an increased callosal angle in the coronal plane [32]. Patients in this group were not suffering from any other neurological, psychiatric, or medical conditions that could potentially explain their presenting symptoms.

We excluded AD patients with a history of head injury, other neurological and/or systemic diseases, major depression, and alcoholism or other substance abuse.

All of the patients underwent a comprehensive familial and clinical history, general and neurological examination, extensive neuropsychological investigation, brain magnetic resonance imaging (MRI) or brain Computed Tomography (TC), and lumbar puncture for CSF collection. Patients diagnosed with iNPH underwent a CSF tap test, a procedure that improves the diagnostic accuracy of iNPH and could predict a favorable response to CSF shunt surgery [33].

The local ethics committee approved the protocol of the study. All participants gave written informed consent to participate in the study.
2.2. CSF Tap Test

The iNPH patients underwent baseline evaluation of gait/balance and cognitive function within 24 h before the lumbar puncture. The baseline evaluation included: Short Physical Performance Battery [34], Mini-Mental State Examination [MMSE] [35], Frontal Assessment Battery [36], Phonemic Fluency Test, and Trail-making Test [37]. The lumbar puncture was performed at 9.00 a.m. with removal of 30–50 mL of CSF. The gait/balance assessment (Short Physical Performance Battery) was repeated 6, 24, and 48 h after the CSF subtraction. The neuropsychological examination (Phonemic Fluency test and Trail Making Test) was repeated 6, 24, and 48 h after the CSF subtraction.

2.3. CSF Biomarkers Analysis

The CSF samples collected by the lumbar puncture were immediately centrifuged and stored at −80 °C until performing the analysis. \( \alpha_4 \beta_{42} \), \( \alpha_4 \beta_{42}/\alpha_4 \beta_{40} \) ratio, t-tau, and p-tau have been measured using a chemiluminescent enzyme immunoassay (CLEIA) analyzer LUMIPULSE G600 (Fujirebio, Tokyo, Japan). Cut-off values for CSF were determined by following Fujirebio guidelines (Diagnostic sensitivity and specificity using clinical diagnosis and follow-up golden standard, 19 November 2018 [38]): \( \alpha_4 \beta_{42} > 670 \, \text{pg/mL}, \alpha_4 \beta_{42}/\alpha_4 \beta_{40} \) ratio > 0.062, t-tau < 400 pg/mL and p-tau < 60 pg/mL. Patients were rated as \( \alpha_4 \beta_{42}^+ \) or \( \alpha_4 \beta_{42}^- \) and \( \alpha_4 \beta_{42}/\alpha_4 \beta_{40}^+ \) and \( \alpha_4 \beta_{42}/\alpha_4 \beta_{40}^- \) if the \( \alpha_4 \beta_{42} \) and \( \alpha_4 \beta_{42}/\alpha_4 \beta_{40} \) were lower or higher than the cut-off values, respectively. Patients were rated as \( \alpha_4 \beta_{42} \) or \( \alpha_4 \beta_{42}^- \) and \( \alpha_4 \beta_{42}/\alpha_4 \beta_{40}^+ \) and \( \alpha_4 \beta_{42}/\alpha_4 \beta_{40}^- \) if the CSF p-tau and t-tau concentrations were higher or lower than cut-off values, respectively [39].

2.4. Statistical Analysis

Patient groups were characterized using means and standard deviations (SD). We tested for normality in the distribution of the data using the Kolmogorov–Smirnov test. Depending on the distribution of the data, we used \( t \)-tests or non-parametric Mann–Whitney \( U \) tests for between-groups comparisons and Pearson’s \( r \) or Spearman’s \( \rho \) for correlations. We used chi-square tests to compare categorical data. We calculated the size effect with Cohen’s \( d \) for normally distributed numeric measures, \( \eta^2 \) for Mann–Whitney \( U \) Test, and Cramer’s \( V \) for categorical data. Receiver operating characteristic (ROC) analyses were performed to evaluate the ability of CSF biomarkers to distinguish between iNPH and AD. Youden’s method was used to detect the best cut-off value and accuracy, sensitivity, and specificity. We used binomial logistic regression to ascertain the contribution of each biomarker in distinguishing iNPH and AD. Bonferroni correction was applied to correct for multiple comparisons. All statistical analyses were performed with SPSS software v.25 (SPSS Inc., Chicago, IL, USA) and the computing environment R 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria, 2013).

3. Results

3.1. Description of the Sample

At onset, all the patients in the iNPH group had balance/gait impairment, 33 (75.00%) had cognitive impairment, and 31 (70.45%) had urinary incontinence. Twenty-three patients (52.27%) had the complete triad, while three patients (6.82%) only had balance/gait impairment. Thirteen out of 44 iNPH patients (29.55%) experienced an improvement in their gait after the CSF tap test, while 31 patients (70.45%) did not. Figure 1 shows correlations among the demographic features and CSF biomarkers in the iNPH and AD groups (Figure 1). Both in AD and iNPH, \( \alpha_4 \beta_{42}/\alpha_4 \beta_{40} \) correlated with \( \alpha_4 \beta_{42} \) and p-tau correlated with t-tau. In the iNPH group \( \alpha_4 \beta_{42}/\alpha_4 \beta_{40} \) also correlated with p-tau. In AD patients, MMSE was significantly correlated with age.
There were no differences in years of education (*p* > 0.05). Cohen's *d* = 0.315, *p* = 0.69) concentrations were significantly lower in the iNPH patients compared to the AD group (*p* = 0.017), but these differences were not statistically significant when adjusted for multiple comparisons (accepted at *p* < 0.003).

Patients in the iNPH group also had lower p-tau (32.13 [17.85] pg/mL vs. 125.52 [63.09] pg/mL, *p* < 0.001, *d* = 1.74) concentrations than patients in the AD group (Table 1, Figure 2). Thirty-one out of 44 iNPH patients and 79 out of 101 AD patients had positive Aβ42 (CSF Aβ42 concentrations below the cut-off value), with no difference in distribution between groups (70.45% [95% C.I. = 56.97:83.94] vs. 78.22% [95% C.I. = 70.17:86.27], *χ²* = 1.01, *p* = 0.315, *V* = 0.083). On the opposite, proportions of a positive Aβ42/Aβ40 ratio, (13.64% [95% C.I. = 3.50:23.78] vs. 93.07% [95% C.I. = 88.12:98.02], *χ²* = 90.35, *p* < 0.001, *V* = 0.79), p-tau (6.82% [95% C.I. = 0.14:27] vs. 88.12% [95% C.I. = 81.81:94.43%], *χ²* = 87.35, *p* < 0.001, *V* = 0.78) and t-tau (11.36 [95% C.I. = 1.99:20.74] vs. 84.16% [95% C.I. = 77.04:91.28], *χ²* = 68.98, *p* < 0.001, *V* = 0.69) concentrations were significantly lower in the iNPH patients compared to the AD group (Table 1, Figure 3).

### 3.2. Comparison between iNPH and AD Groups

The iNPH patients were older than the AD (*p* = 0.044, Cohen's *d* = −0.001) and had a lower frequency of APOE ε4+ (*χ²* = 5.74, *p* = 0.017), but these differences where not statistically significant when adjusted for multiple comparisons (accepted at *p* < 0.003). There were no differences in years of education (*p* = 0.519, Cohen's *d* = −0.135). AD patients had lower mean MMSE scores than iNPH patients (24.25 [SD = 4.02] vs. 19.57 [SD = 4.85], *p* < 0.001, *d* = 1.05). There were no differences in Aβ42 concentration between iNPH and AD (624.89 [316.30] pg/mL vs. 563.49 [236.94] pg/mL, *p* = 0.119, *d* = 0.22), while the Aβ42/Aβ40 ratios were significantly higher in iNPH than in AD (0.09 [0.02] vs. 0.04 [0.02], *p* < 0.001, *d* = 2.21). Patients in the iNPH group also had lower p-tau (32.13 [17.85] pg/mL vs. 125.52 [63.09] pg/mL, *p* < 0.001, *d* = 2.01) and t-tau (242.66 [205.59] pg/mL vs. 768.79 [374.22] pg/mL, *p* < 0.001, *d* = 1.74) concentrations than patients in the AD group (Table 1, Figure 2).

Figure 1. Correlation matrix. Values quoted in the correlation matrix are Pearson’s *r* correlation coefficients. Statistical significance received a Bonferroni adjustment and was accepted at *p* < 0.01 (significant correlations were reported as underlined characters). Color maps represent Pearson’s *r* correlation coefficients. *p* < 0.05, **p* < 0.01.

### Table 1.

| Comparison | iNPH | AD |
|------------|------|----|
| Age, mean (SD) | 73.92 (7.42) | 71.28 (6.83) |
| Sex (women/men) | 26/18 | 50/51 |
| Aβ42/Aβ40 | 0.10 | 0.47** |
| Aβ42 | 0.40** | 0.133 |
| t-tau | 0.03 | 0.32* |
| p-tau | −0.38* | 0.29 |
| APOE ε4+ | 0.68** | 0.21* |
| Concentrations | 1.74 | 0.017 |
| Concentrations | 0.017 | 0.017 |

**Figure 1.** Correlation matrix. Values quoted in the correlation matrix are Pearson’s *r* correlation coefficients. Statistical significance received a Bonferroni adjustment and was accepted at *p* < 0.01 (significant correlations were reported as underlined characters). Color maps represent Pearson’s *r* correlation coefficients. *p* < 0.05, **p* < 0.01.

**Table 2.** Comparison of demographic variables and CSF biomarker values between iNPH and AD groups.

| Comparison | iNPH | AD |
|------------|------|----|
| Age, mean (SD) | 73.92 (7.42) | 71.28 (6.83) |
| Sex (women/men) | 26/18 | 50/51 |
| Aβ42/Aβ40 | 0.10 | 0.47** |
| Aβ42 | 0.40** | 0.133 |
| t-tau | 0.03 | 0.32* |
| p-tau | −0.38* | 0.29 |
| APOE ε4+ | 0.68** | 0.21* |
| Concentrations | 1.74 | 0.017 |
| Concentrations | 0.017 | 0.017 |
Table 1. Comparison of demographic variables and CSF biomarker values between iNPH and AD patients.

|                       | iNPH                  | AD                       |
|-----------------------|-----------------------|--------------------------|
| **N**                 | 44                    | 101                      |
| Age, mean (SD)        | 73.92 (7.42)          | 71.28 (6.83)             |
| Sex (women/men)       | 26/18                 | 50/51                    |
| Years of education, mean (SD) | 9.71 (3.94) | 9.98 (4.21)             |
| APOE ε4+, % (95 CI %) | 24.14 (8.56:39.71)    | 49.45 (39.18:59.72)      |
| MMSE, mean (SD)       | 24.25 (4.02) a        | 19.57 (4.85) a           |
| Aβ42 (pg/mL), mean (SD) | 624.89 (316.30)    | 563.49 (236.94)          |
| Aβ42/Aβ40, mean (SD)  | 0.09 (0.02) b         | 0.04 (0.02) b            |
| p-tau (pg/mL), mean (SD) | 32.13 (17.85) c  | 125.52 (63.09) c        |
| t-tau (pg/mL), mean (SD) | 242.66 (205.57) d    | 768.79 (374.22) d       |
| Aβ42+, % (95% C.I.)   | 70.45 (56.97:83.94)   | 78.22 (70.17:86.27)      |
| Aβ42/Aβ40+, % (95% C.I.) | 13.64 (3.50:23.78) e | 93.07 (88.12:98.02) e   |
| T+, % (95% C.I.)      | 6.82 (0.14:27) f      | 88.12 (81.81:94.43) f    |
| N+, % (95% C.I.)      | 11.36 (1.99:20.74) g  | 84.16 (77.04:91.28) g    |

Values quoted in the table are mean (±SD) or n (%). Statistical significance received a Bonferroni adjustment and was accepted at \( p < 0.003 \).

- a \( p < 0.001, d = 1.05 \);
- b \( p < 0.001, d = 2.21 \);
- c \( p < 0.001, d = 2.01 \);
- d \( p < 0.001, d = 1.74 \);
- e \( \chi^2 = 90.35, V = 0.79 \);
- f \( \chi^2 = 87.35, V = 0.87 \);
- g \( \chi^2 = 68.98, V = 0.69 \).

Figure 2. Comparison of the CSF biomarker concentrations and Aβ42/Aβ40 ratio between iNPH and AD. Values quoted on the y-axis indicate the CSF concentration (expressed as pg/mL) for Aβ42, p-tau, t-tau, and the value of the ratio for the Aβ42/Aβ40. *p*-values and Cohen’s *d* are reported. Statistical significance received a Bonferroni adjustment and was accepted at \( p < 0.003 \).
tau, t-tau, and the value of the ratio for the \( A_\beta 42 / A_\beta 40 \). \( p \)-values and Cohen's \( d \) are reported. Statistical significance received a Bonferroni adjustment and was accepted at \( p < 0.003 \).

Thirty-one out of 44 iNPH patients and 79 out of 101 AD patients had positive \( A_\beta 42 \) (CSF \( A_\beta 42 \) concentrations below the cut-off value), with no difference in distribution between groups (70.45% [95% C.I. = 56.97:83.94] vs. 78.22% [95% C.I. 70.17:86.27], \( \chi^2 = 1.01, p = 0.315, V = 0.083 \)). On the opposite, proportions of a positive \( A_\beta 42 / A_\beta 40 \) ratio, (13.64% [95% C.I. = 3.50:23.78] vs. 93.07% [95% C.I. = 88.12:98.02], \( \chi^2 = 90.35, p < 0.001, V = 0.79 \)), \( p \)-tau (6.82% [95% C.I. = 0:14.27] vs . 88.12% [95% C.I. 81.81:94.43%], \( \chi^2 = 87.35, p < 0.001, V = 0.78 \)) and t-tau (11.36 [95% C.I. = 1.99:20.74] vs. 84.16% [95% C.I. = 77.04:91.28], \( \chi^2 = 68.98, p < 0.001, V = 0.69 \)) concentrations were significantly lower in the iNPH patients compared to the AD group (Table 1, Figure 3).

**3.3. CSF Biomarkers Accuracy in Distinguishing between iNPH and AD**

Table 2 summarizes the area under the curve (AUC), accuracy, sensitivity, and specificity of each CSF biomarker in distinguishing iNPH and AD patients. We identified the cut-off values by Youden’s method. The \( A_\beta 42 / A_\beta 40 \) ratio, \( p \)-tau, and t-tau showed very high accuracy without differences between the three biomarkers, as showed by the intersection of the 95% confidence intervals. \( A_\beta 42 \) was not able to distinguish between iNPH and AD (Figure 4).

**Table 2. CSF biomarker accuracy.**

| Biomarker     | Cut-Off | AUC | Accuracy, % (CI.95%) | Sensitivity, % (CI.95%) | Specificity, % (CI.95%) |
|---------------|---------|-----|----------------------|------------------------|-------------------------|
| \( A_\beta 42 \) | 776.34  | 0.567 | 64.14 (56.33:71.95)  | 84.16 (78.22:90.10)   | 18.18 (11.90:24.46)   |
| \( A_\beta 42 / A_\beta 40 \) | 0.068   | 0.943 | 86.21 (80.60:91.82)  | 87.13 (81.68:92.58)   | 84.09 (78.14:90.04)   |
| \( p \)-tau   | 65.24   | 0.969 | 88.28 (83.04:93.52)  | 95.45 (92.06:98.84)   | 85.15 (79.36:90.94)   |
| t-tau         | 509.09  | 0.941 | 80.69 (74.27:87.11)  | 93.18 (89.08:97.28)   | 75.25 (68.23:82.27)   |

Cut-off values were estimated by Youden’s method. Area under the curve (AUC), accuracy, sensitivity, and specificity for each biomarker are reported. Accuracy, sensitivity, and specificity are expressed as percentages (95% C.I.).
p-tau 65.24 0.969 88.28 (83.04:93.52) 95.45 (92.06:98.84) 85.15 (79.36:90.94)
t-tau 509.09 0.941 80.69 (74.27:87.11) 93.18 (89.08:97.28) 75.25 (68.23:82.27)

Cut-off values were estimated by Youden’s method. Area under the curve (AUC), accuracy, sensitivity, and specificity for each biomarker are reported. Accuracy, sensitivity, and specificity are expressed as percentages (95% C.I.).

Figure 4. ROC curves for the accuracy of $A\beta_{42}$, $A\beta_{42}/A\beta_{40}$, p-tau, and t-tau in distinguishing iNPH and AD. Colored shapes indicate 95% C.I.

3.4. Logistic Regression Models

To ascertain the effect of each biomarker in discriminating between iNPH and AD adjusting for age, we performed a multivariate logistic regression model including age and CSF biomarker concentrations as independent variables. The regression model was statistically significant ($\chi^2 = 137.19, p < 0.001$). The model explained 86.53% (Nagelkerke $R^2$) of the variance in progression. The accuracy of the model in distinguishing between AD and iNPH was 93.79% (95% C.I. = 89.86:97.72) (sensitivity = 96.04% [95% C.I. = 92.87:99.21], specificity = 88.64% [95% C.I. = 83.47:93.81]). The $A\beta_{42}/A\beta_{40}$ ratio was shown as the only variable which significantly contributed to the model, independent of confounding factors ($B = -128.38$, S.E. = 47.83, $p = 0.007$) (Table 3).

We performed the same analysis considering CSF biomarkers after dichotomization according to cut-off values (Table 3). The regression model was statistically significant ($\chi^2 = 128.67, p < 0.001$). The model explained 83.21% (Nagelkerke $R^2$) of the variance in progression. Age ($B = -0.15$, S.E. = 0.06, $p = 0.013$), $A\beta_{42}/A\beta_{40}$ ($B = 4.37$, S.E. = 1.06, $p < 0.001$) and p-tau ($B = 5.05$, S.E. = 1.58, $p = 0.001$) significantly contributed to the model (Table 3).
Table 3. Multivariate logistic regression models.

|                           | B     | S.E.  | p    | OR    | 95% C.I. Lower | 95% C.I. Upper |
|---------------------------|-------|-------|------|-------|----------------|----------------|
|                           |       |       |      |       |                |                |
|                           | CSF biomarkers (quantitative values) |       |      |       |                |                |
| Age                       | −0.18 | 0.08  | 0.024| 0.83  | 0.71           | 0.98           |
| Aβ42                      | 0.01  | 0.00  | 0.081| 1.00  | 0.99           | 1.01           |
| Aβ42/Aβ40                 | −128.38| 47.83 | 2.013×10⁻³¹ | 3.44×10⁻⁹⁷ | 9.03×10⁻⁸     |                |
| p-tau                     | 0.04  | 0.03  | 0.193| 1.04  | 0.98           | 1.09           |
| t-tau                     | 0.00  | 0.00  | 0.347| 1.07  | 0.99           | 1.01           |
|                           |       |       |      |       |                |                |
| χ² = 137.19, p < 0.001, Nagelkerke R² = 86.53% |       |      |      |       |                |                |
|                           |       |       |      |       |                |                |
|                           | CSF biomarkers (dichotomized values) |       |      |       |                |                |
| Age                       | −0.15 | 0.06  | 0.013| 0.86  | 0.76           | 0.97           |
| A (Aβ42+)                 | −2.06 | 1.21  | 0.092| 0.13  | 0.01           | 1.35           |
| A (Aβ42+/Aβ40+)           | 4.37  | 1.06  | <0.001| 79.20  | 9.89           | 643.36         |
| T*                        | 5.05  | 1.58  | 0.001| 155.78| 7.09           | 3420.53        |
| N*                        | −1.28 | 1.46  | 0.381| 0.278 | 0.02           | 4.86           |
|                           |       |       |      |       |                |                |
| χ² = 128.67, p < 0.001, Nagelkerke R² = 83.21% |       |      |      |       |                |                |

Regression Coefficients (B), Standard errors (S.E), p-value (p), Odds Ratio (OR), and 95% Confidence Intervals (95% C.I.) for covariates included in the logistic regression models are reported. Statistical significance received a Bonferroni adjustment and being accepted at the p < 0.01, highlighted in bold.

3.5. Comparison between iNPH and AD with Positive Aβ42

To explore the meaning of positive Aβ42 in iNPH patients, we compared the AD and iNPH groups and considered only patients who had positive Aβ42 (31 iNPH/Aβ42+ vs. 79 AD/Aβ42+, Table 4). The iNPH/Aβ42+ had higher MMSE than AD/Aβ42+ (24.68 [3.43] vs. 19.53 [3.42], p < 0.001, d = 1.50). There was no difference in age. The lower frequency of APOE ε4 in iNPH than in AD/Aβ42+ patients was not statistically significant when adjusted for multiple comparison (23.81 [95% C.I. = 5.59:42.03], χ² = 4.52, p = 0.033, V = 0.22). The CSF biomarker concentrations (Aβ42/Aβ40, p-tau, and t-tau) were different between iNPH/Aβ42+ and AD/Aβ42+ (Figure 5). In particular among 31 iNPH/Aβ42+, only six patients (19.35% [95% C.I. = 5.45:33.26]) had positive Aβ42/Aβ40, two patients (6.45% [95% C.I. = 0:15.10]) had positive p-tau, and four patients (12.90% [95% C.I. = 1.10:24.70]) had positive t-tau. In contrast, 76 out of 79 AD/Aβ42+ patients had positive Aβ42/Aβ40 (96.20% [95% C.I. = 91.99:100]), 69 had positive p-tau (87.34% [95% C.I. = 80.01:94.67]), and 66 had positive t-tau (83.54% [95% C.I. = 75.37:91.72]).

Table 4. Comparison of demographic variables and CSF biomarker values between iNPH/Aβ42+ and AD/Aβ42+ patients.

|                           | iNPH/Aβ42+ | AD/Aβ42+ |
|---------------------------|------------|----------|
| N                          | 31         | 79       |
| Age, mean (SD)            | 73.08 (8.24)| 70.95 (6.97) |
| Sex (women/men)           | 19/12      | 37/42    |
| Years of education, mean (SD) | 9.73 (3.77) | 10.21 (4.39) |
| APOE ε4, % (95 CI %)      | 23.81 (5.59:42.03)| 50.00 (38.45:61.55) |
| MMSE, mean (SD)           | 24.68 (4.02) | 19.53 (3.42) |
| Aβ42 (pg/mL), mean (SD)   | 482.48 (110.44)| 462.76 (116.18) |
| Aβ42/Aβ40, mean (SD)      | 0.08 (0.12) | 0.04 (0.01) |
| p-tau (pg/mL), mean (SD)  | 30.44 (19.10) | 120.02 (60.25) |
| t-tau (pg/mL), mean (SD)  | 244.74 (238.07) | 724.65 (338.935) |
| Aβ42/Aβ40+, % (95% C.I.)  | 13.64 (3.50:23.78) | 93.07 (88.12:98.02) |
| T*, % (95% C.I.)          | 6.82 (0.14:27) | 88.12 (81.81:94.43) |
| N*, % (95% C.I.)          | 11.36 (1.99:20.74) | 84.16 (77.04:91.28) |

Values quoted in the table are mean (±SD) or n (%). Statistical significance received a Bonferroni adjustment and was accepted at p < 0.003. a p < 0.001, d = 1.50; b p < 0.001, d = 2.72; c p < 0.001, d = 2.00; d p < 0.001, d = 1.64; e χ² = 69.29, p < 0.001, V = 0.79; f χ² = 63.66, p < 0.001, V = 0.76; g χ² = 48.01, p < 0.001, V = 0.66.
Figure 5. Comparison of CSF biomarker concentrations and \( \text{A}\beta_{42}/\text{A}\beta_{40} \) ratio between iNPH/\( \text{A}\beta_{42}^+ \) and \( \text{AD}/\text{A}\beta_{42}^+ \). The values quoted on the y-axis indicate the CSF concentration (expressed as pg/mL) for \( \text{A}\beta_{42} \), p-tau, and t-tau.

3.6. Features of iNPH Patients Classified According to \( \text{A}\beta_{42} \) and \( \text{A}\beta_{42}/\text{A}\beta_{40} \) Status

We classified iNPH patients according to \( \text{A}\beta_{42} \) status (30 \( \text{A}\beta_{42}^+ \) and 14 \( \text{A}\beta_{42}^- \)). We found no differences in the demographic features and the \( \text{A}\beta_{42}/\text{A}\beta_{40} \), p-tau, and t-tau values. \( \text{APOE} \) e4 allele was not associated with positive \( \text{A}\beta_{42} \) status. There were no differences in proportion of cognitive impairment and urinary incontinence between \( \text{A}\beta_{42}^+ \) and \( \text{A}\beta_{42}^- \). When we compared patients according to \( \text{A}\beta_{42}/\text{A}\beta_{40} \) status (6 \( \text{A}\beta_{42}/\text{A}\beta_{40}^+ \) and 38 \( \text{A}\beta_{42}/\text{A}\beta_{40}^- \), Table 5), patients with positive \( \text{A}\beta_{42}/\text{A}\beta_{40}^+ \) had higher p-tau (59.46 pg/mL [23.74] vs. 27.47 [11.81], \( p < 0.001, d = 1.87 \)) than \( \text{A}\beta_{42}/\text{A}\beta_{40}^- \) patients. Furthermore, \( \text{A}\beta_{42}/\text{A}\beta_{40}^+ \) had higher frequencies of positive p-tau (33.33% [95% C.I. = 0.71.05] vs. 2.63% [C.I. 95% = 0.7.72, \( \chi^2 = 7.68, p = 0.006, V = 0.41 \)) and t-tau (50.00% [95% C.I. = 9.99.90.01] vs. 5.26% [C.I. 95% = 0.12.36, \( \chi^2 = 10.29, p = 0.001, V = 0.48 \)) as compared to \( \text{A}\beta_{42}/\text{A}\beta_{40}^- \). Notably, all the patients in the \( \text{A}\beta_{42}/\text{A}\beta_{40}^+ \) group had positive \( \text{A}\beta_{42} \), while four had negative p-tau. Only one patient with positive p-tau had negative \( \text{A}\beta_{42}/\text{A}\beta_{40} \). Urinary incontinence was more frequent in the \( \text{A}\beta_{42}/\text{A}\beta_{40}^+ \) group (76.32% [95% C.I. = 62.80.89.83] vs. 33.33% [95% C.I. 4.39.71.05]), \( \chi^2 = 4.56, p = 0.032, V = 0.323 \), while there were no differences in cognitive impairment between \( \text{A}\beta_{42}/\text{A}\beta_{40}^+ \) and \( \text{A}\beta_{42}/\text{A}\beta_{40}^- \). Particularly in the \( \text{A}\beta_{42}/\text{A}\beta_{40}^- \) group, all the patients had cognitive impairment, but only two out of the six had urinary incontinence.
Table 5. Comparison of demographic variables and CSF biomarkers values between iNPH Aβ_{42}/Aβ_{40−} and iNPH Aβ_{42}/Aβ_{40+} groups.

|                      | iNPH Aβ_{42}/Aβ_{40−} | iNPH Aβ_{42}/Aβ_{40+} |
|----------------------|------------------------|------------------------|
| N (%)                | 38 (86.36%)            | 6 (13.64%)             |
| Age, mean (SD)       | 73.36 (7.21)           | 77.61 (8.61)           |
| Sex (women/men)      | 24/14                  | 2/4                    |
| Years of education, mean (SD) | 9.54 (3.94)          | 10.60 (4.28)           |
| APOE ε4+, % (95 CI %) | 20.00 (4.32:35.68)     | 50.00 (1.00:99.00)     |
| MMSE, mean (SD)      | 24.52 (4.14)           | 22.80 (3.35)           |
| Aβ_{42} (pg/mL), mean (SD) | 644.66 (335.17)     | 499.67 (85.63)         |
| p-tau (pg/mL), mean (SD) | 27.47 (11.82)        | 39.46 (23.74)          |
| A (Aβ_{42}+), % (95% C.I) | 65.79 (50.71:80.87)  | 100                    |
| T+, % (95% C.I.)     | 2.63 (0.71)            | 33.33 (0.71:0.05)      |
| N+, % (95% C.I.)     | 5.26 (0.12:36)         | 50.00 (9.99:90.01)     |
| Cognitive impairment, % (95% C.I.) | 71.05 (56.63:85.47)  | 100                    |
| Urinary incontinence, % (95% C.I.) | 76.32 (62.80:89.83)  | 33.33 (43.9:71.05)     |
| Response to CSF tap test, % (95% C.I.) | 28.95 (14.53:43.37) | 33.33 (0.71:0.05)      |

Values quoted in the table are mean (±SD) or n (%). Statistical significance received a Bonferroni adjustment and being accepted at the p < 0.004). a p < 0.001, d = 1.87; b χ² = 7.68, p = 0.006, V = 0.41; c χ² = 10.29, p = 0.032, V = 0.323.

3.7. Association between Clinical Features and CSF Biomarkers

The iNPH patients who showed cognitive impairment had lower Aβ_{42}/Aβ_{40} (0.087 [0.022] vs. 0.097 [0.009], p = 0.036, d = 0.61) and higher p-tau (35.48 [18.00] vs. 22.08 [13.62], p = 0.029, d = 0.84) than patients without cognitive impairment at onset. CSF biomarker concentrations were not associated with urinary incontinence, nor with response to CSF tap test.

4. Discussion

Our first result confirmed that patients with iNPH have CSF Aβ_{42} concentrations comparable to AD and lower concentrations of p-tau and t-tau than AD, as widely described in previous studies [21,40–42]. In more detail, about 70% of patients in our series had positive CSF Aβ_{42}, while p-tau and t-tau were positive in 7% and 11% of patients, respectively, which is consistent with a previous report by Santangelo et al. [21]. In contrast, we showed that Aβ_{42}/Aβ_{40} was higher in iNPH than AD. Only 14% of iNPH patients had a Aβ_{42}/Aβ_{40} ratio in the pathologic range (below the cut-off value), compared to 93% in the AD group.

When we estimated the diagnostic values of each biomarker, Aβ_{42}/Aβ_{40}, p-tau, and t-tau had very good accuracy in distinguishing between iNPH and AD, with no significant differences between the biomarkers. The logistic regression analysis demonstrated that Aβ_{42}/Aβ_{40} and p-tau contributed to distinguishing iNPH patients from AD patients, in line with other works [43,44], with the notion that these biomarkers are more specific for AD than Aβ_{42} and t-tau [45,46]. Nevertheless, we would like to point out that, among iNPH patients with positive Aβ_{42}/Aβ_{40}, four had negative p-tau, while only one iNPH with positive p-tau had negative Aβ_{42}/Aβ_{40}. For the purposes of clinical practice, this remark mainly addresses to consider Aβ_{42}/Aβ_{40} to identify AD pathology in iNPH patients and to use p-tau as a support biomarker. Based on the evidence that p-tau and t-tau can be increased in iNPH in association with long disease duration [47] and poor response at the CSF tap test [48], other authors suggested that p-tau and t-tau biomarkers may be prognostic factors more than diagnostic tools [49]. We aim to test this hypothesis and clarify the role of p-tau and t-tau in further works with wider samples. Notably, the cut-off values identified in our sample by automatized method were consistent with the cut-off values adopted according to LUMIPULSE producer guidelines. This result suggests using
the same cut-off values adopted in clinical practice for the diagnosis of AD, as well as to distinguish iNPH from AD.

Even though several studies already showed that Aβ42 is lower in iNPH patients than in healthy controls, the discrepancy between Aβ42 and Aβ42/Aβ40 was shown only by a few previous studies [43,50]. Our results confirm these reports and are in line with the evidence that in iNPH patients, the CSF levels of all the amyloid precursor protein (APP) fragments (Aβ38, Aβ40, Aβ42, sAPPα, and sAPPβ) are decreased compared to controls [11,12,30]. In contrast, the levels of Aβ42 in AD are associated with slightly increased or steady levels of Aβ40 [29]. Consequently, the ratio between Aβ42 and Aβ40 is supposed to be normal in iNPH patients without AD copathology, as reported by previous studies [43,50] and described in our sample. In particular, we showed that in 86% of iNPH patients with pathologic Aβ42, the Aβ42/Aβ40 ratio was normal, suggesting that in the majority of cases, the reduction of Aβ42 is associated with an equal reduction of Aβ40. Furthermore, we showed that iNPH patients with positive Aβ42 had lower CSF p-tau and t-tau concentrations than AD patients. In particular, only four out of 31 iNPH patients with positive Aβ42 also had positive t-tau and two out of these patients had positive p-tau. This evidence may support the hypothesis that Aβ42 in iNPH patients does not indicate AD copathology.

The role of positive Aβ42/Aβ40 in iNPH is more difficult to interpret. We found that iNPH patients with positive Aβ42/Aβ40 had higher p-tau and t-tau concentrations than iNPH patients with negative Aβ42/Aβ40. In line with a previous result [43], we also found that iNPH patients who showed cognitive impairment had lower Aβ42/Aβ40 and higher p-tau than patients without cognitive impairment. Moreover, 100% of iNPH patients with positive Aβ42/Aβ40 also had positive Aβ42, which might suggest that, in this group of patients, the low Aβ42/Aβ40 ratio is associated with a higher reduction of Aβ42 than Aβ40, as found in the AD patients [29]. Finally, we found that urinary incontinence was uncommon in iNPH with positive Aβ42/Aβ40 (only two out of six), as most of the patients in this group showed only gait/balance disturbance and cognitive impairment, suggesting a possible misdiagnosis. Considering this evidence, positive Aβ42/Aβ40 might indicate a coexistent AD pathology in patients affected by iNPH or a diagnosis of AD dementia.

This hypothesis is supported by many studies which demonstrated that the Aβ42/Aβ40 ratio is more accurate than Aβ42 in identifying AD pathology [51,52].

If confirmed by further works, our results might suggest consideration of positive Aβ42 with negative Aβ42/Aβ40 and p-tau as the typical CSF profile of iNPH. On the contrary, positive CSF Aβ42/Aβ40 should lead to suspicion of an underlying AD pathology.

This study had some limitations: (i) the relatively small sample size, especially when we classified patients according to Aβ42/Aβ40 status, which limits the impact of our conclusions; (ii) quantitative scores of gait/balance assessment are not available; (iii) data about gait/balance disturbance and urinary incontinence are not available for the AD group. However, we provided several pieces of evidence which may serve as starting points for future studies. As already stated, this is one of the first studies assessing Aβ42/Aβ40 in differential diagnostics of iNPH. Moreover, despite the small sample size, this is the first study to have classified patients according to Aβ42/Aβ40 status. Many studies divided iNPH patients according to their Aβ status, but did not distinguish between Aβ42 and Aβ42/Aβ40. As shown, Aβ42 could not be considered as an index of Aβ pathology in iNPH. On the other hand, considering only Aβ42/Aβ40 allowed us to classify iNPH patients as carriers or non-carriers of Aβ pathology with a higher accuracy.

5. Conclusions

We showed that positive CSF Aβ42 with negative Aβ42/Aβ40, p-tau, and t-tau is a frequently encountered finding in iNPH and should be considered as a typical CSF profile of iNPH. On the other hand, positive Aβ42/Aβ40 is uncommon in iNPH and is associated with a prevalent cognitive syndrome. Our results are in line with previous evidence and suggest that clinicians should not diagnose AD pathology in patients with iNPH.
and isolated positive CSF Aβ42. On the contrary, positive Aβ42/Aβ40 in iNPH patients, especially when associated with positive p-tau, may lead to suspicion of a coexistent AD pathology or revision of the diagnosis of iNPH.

**Author Contributions:** Conceptualization, S.M. and V.B.; methodology, S.M., F.E. and L.M.D.R.; software, S.M.; formal analysis, S.M.; investigation, S.M., F.E., L.M.D.R., S.P., J.B., G.G. (Giulia Giacomucci) and V.B.; resources, S.M., S.P., B.V., A.I., C.P., C.F., S.S., G.P., A.D.P. and V.B.; data curation, S.M., F.E., S.P., L.M.D.R., V.M., C.M., G.G. (Giulia Giacomucci), J.B. and G.G. (Giulia Galdo); writing—original draft preparation, S.M.; writing—review and editing, S.M. and V.B.; visualization, A.D.P., G.P., S.S. and B.N.; supervision, V.B.; project administration, V.B.; funding acquisition, S.S. and B.N. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded by RICATEN22 (Ateneo Università di Firenze, fondi Ateneo 2022) The funding source had no such involvement in the study design.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Azienda Ospedaliero-Universitaria Careggi.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** An anonymized data that support the findings of this study will be shared by request from any qualified investigator.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Williams, M.A.; Malm, J. Diagnosis and treatment of idiopathic normal pressure hydrocephalus. *Continuum* 2016, 22, 579–599. [CrossRef]
2. Hakim, S.; Adams, R.D. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. *J. Neurol. Sci.* 1965, 2, 307–327. [CrossRef]
3. Toma, A.K.; Papadopoulos, M.C.; Stapleton, S.; Kitchen, N.D.; Watkins, L.D. Systematic review of the outcome of shunt surgery in idiopathic normal-pressure hydrocephalus. *Acta Neurochir.* 2013, 155, 1977–1980. [CrossRef] [PubMed]
4. Espay, A.J.; Da Prat, G.A.; Dwivedi, A.K.; Rodriguez-Porcel, F.; Vaughan, J.E.; Rosso, M.; Devoto, J.L.; Duker, A.P.; Masellis, M.; Smith, C.D.; et al. Deconstructing normal pressure hydrocephalus: Venticulomegaly as early sign of neurodegeneration. *Ann. Neurol.* 2017, 82, 503–513. [CrossRef] [PubMed]
5. Jaraj, D.; Rabiei, K.; Marlow, T.; Jensen, C.; Skoog, I.; Wikkelso, C. Prevalence of idiopathic normal-pressure hydrocephalus. *Neurology* 2014, 82, 1449–1454. [CrossRef]
6. Molde, K.; Söderström, L.; Laurell, K. Parkinsonian symptoms in normal pressure hydrocephalus: A population-based study. *J. Neurol.* 2017, 264, 2141–2148. [CrossRef]
7. Relkin, N.; Marmarou, A.; Klinge, P.; Bergsneider, M.; Black, P.M. Diagnosing idiopathic normal-pressure hydrocephalus. *Neurosurgery* 2005, 57, S4–S16. [CrossRef] [PubMed]
8. Schirinzì, T.; Sancesario, G.M.; Ialongo, C.; Imbriani, P.; Madeo, G.; Toniolo, S.; Martorana, A.; Pisanì, A. A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus. *Front. Neurol.* 2015, 6, 86. [CrossRef]
9. Tullberg, M.; Jensen, C.; Ekholm, S.; Wikkelso, C. Normal pressure hydrocephalus: Vascular white matter changes on mr images must not exclude patients from shunt surgery. *AJNR Am. J. Neuroradiol.* 2001, 22, 1665–1673.
10. Blennow, K.; Zetterberg, H.; Fagan, A.M. Fluid biomarkers in alzheimer disease. *Cold Spring Harb. Perspect. Med.* 2012, 2, a006221. [CrossRef]
11. Chen, Z.; Liu, C.; Zhang, J.; Relkin, N.; Xing, Y.; Li, Y. Cerebrospinal fluid aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: A systematic review and meta-analysis. *Fluids Barriers CNS* 2017, 14, 13. [CrossRef] [PubMed]
12. Jeppsson, A.; Höltta, M.; Zetterberg, H.; Blennow, K.; Wikkelso, C.; Tullberg, M. Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus. *Fluids Barriers CNS* 2016, 13, 13. [CrossRef] [PubMed]
13. Graff-Radford, N.R. Alzheimer csf biomarkers may be misleading in normal-pressure hydrocephalus. *Neurology* 2014, 83, 1573–1575. [CrossRef] [PubMed]
14. Ringstad, G.; Vatnehol, S.A.S.; Eide, P.K. Glymphatic MRI in idiopathic normal pressure hydrocephalus. *Brain* 2017, 140, 2691–2705. [CrossRef]
15. Cabral, D.; Beach, T.G.; Vedders, L.; Sue, L.I.; Jacobson, S.; Myers, K.; Sabbagh, M.N. Frequency of Alzheimer’s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus. *Alzheimer’s Dement.* 2011, 7, 509–513. [CrossRef] [PubMed]
16. Leinonen, V.; Koivisto, A.M.; Savolainen, S.; Rummukainen, J.; Tamminen, J.N.; Tillgren, T.; Vainikka, S.; Pyykkö, O.T.; Mölsä, J.; Fraunberg, M.; et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer’s disease. *Ann. Neurol.* 2010, 68, 446–453. [CrossRef]

17. Libard, S.; Laurell, K.; Cesaroni, K.G.; Alafuzzof, I. Progression of Alzheimer’s disease-related pathology and cell counts in a patient with idiopathic normal pressure hydrocephalus. *J. Alzheimer’s Dis.* 2018, 61, 1451–1462. [CrossRef]

18. Kazui, H.; Hirono, N.; Hashimoto, M.; Nakano, Y.; Matsumoto, K.; Takatsuki, Y.; Mori, E.; Ikejiri, Y.; Takeda, M. Symptoms underlying unawareness of memory impairment in patients with mild Alzheimer’s disease. *J. Geriatr. Psychiatry Neurol.* 2006, 19, 3–12. [CrossRef]

19. Lim, T.S.; Choi, J.Y.; Park, S.A.; Yoon, Y.C.; Lee, H.Y.; Kim, B.G.; Joo, I.S.; Huh, K.; Moon, S.Y. Evaluation of coexistence of Alzheimer’s disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers. *BMC Neurol.* 2014, 14, 66. [CrossRef][PubMed]

20. Niermeyer, M.; Gaudet, C.; Mallory, P.; Piryatinsky, I.; Salloway, S.; Klinge, P.; Lee, A. Frontal behavior syndromes in idiopathic normal pressure hydrocephalus as a function of Alzheimer’s disease biomarker status. *J. Int. Neuropsychol. Soc.* 2020, 26, 883–893. [CrossRef][PubMed]

21. Santangelo, R.; Cecchetti, G.; Bernasconi, M.P.; Cardamone, R.; Barbieri, A.; Pinto, P.; Passerini, G.; Scomazzoni, F.; Comi, G.; Magnani, G. Cerebrospinal fluid amyloid-β42, total tau and phosphorylated tau are low in patients with normal pressure hydrocephalus: Analogies and differences with Alzheimer’s disease. *J. Alzheimer’s Dis.* 2017, 60, 183–200. [CrossRef][PubMed]

22. Abu Hamdeh, S.; Virhammar, J.; Sehlin, D.; Alafuzzof, I.; Cesaroni, K.G.; Marklund, N. Brain Tissue Aβ42 Levels are linked to shunt response in idiopathic normal pressure hydrocephalus. *J. Neurol Surg.* 2018, 130, 121–129. [CrossRef][PubMed]

23. Azuma, S.; Kazui, H.; Kanemoto, H.; Suzuki, Y.; Sato, S.; Suehiro, T.; Matsumoto, T.; Yoshiyama, K.; Kishima, H.; Shimosegawa, E.; et al. Cerebral blood flow and Alzheimer’s disease-related biomarkers in cerebrospinal fluid in idiopathic normal pressure hydrocephalus. *Psychogeriatrics* 2019, 19, 527–538. [CrossRef][PubMed]

24. Hong, Y.J.; Kim, M-J.; Jeong, E.; Kim, J-E.; Hwang, J.; Lee, J-I.; Lee, J-H.; Na, D.L. Preoperative biomarkers in patients with idiopathic normal pressure hydrocephalus showing a favorable shunt surgery outcome. *J. Neurol. Sci.* 2018, 387, 21–26. [CrossRef][PubMed]

25. Jang, H.; Park, S.B.; Kim, Y.; Kim, K.W.; Lee, J.I.; Kim, S.T.; Lee, K.H.; Kang, E-S.; Choe, Y.S.; Seo, S.W.; et al. Prognostic Value of Amyloid PET Scan in Normal Pressure Hydrocephalus. *J. Neurol.* 2018, 265, 63–73. [CrossRef]

26. Müller-Schmitz, K.; Krasavina-Loka, N.; Yardimci, T.; Lipka, T.; Kolman, A.G.J.; Robbers, S.; Menge, T.; Kujovic, M.; Seitz, R.J. Normal Pressure Hydrocephalus Associated with Alzheimer’s Disease. *Ann. Neurol.* 2020, 88, 703–711. [CrossRef]

27. Portelius, E.; Westman-Brinkmalm, A.; Zetterberg, H.; Blennow, K. Determination of Beta-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry. *J. Proteome Res.* 2006, 5, 1010–1016. [CrossRef]

28. Hansson, O.; Lehmann, S.; Otto, M.; Zetterberg, H.; Lewczuk, P. Advantages and Disadvantages of the Use of the CSF Amyloid β (Aβ) 42/40 Ratio in the Diagnosis of Alzheimer’s Disease. *Alzheimer’s Res. Ther.* 2019, 11, 34. [CrossRef][PubMed]

29. Blennow, K.; Hampel, H.; Weiner, M.; Zetterberg, H. Cerebrospinal Fluid and Plasma Biomarkers in Alzheimer Disease. *Nat. Rev. Neurol.* 2010, 6, 131–144. [CrossRef][PubMed]

30. Jeppsson, A.; Zetterberg, H.; Blennow, K.; Wikkelso, C. Idiopathic Normal-Pressure Hydrocephalus: Pathophysiology and Diagnosis by CSF Biomarkers. *Neurology* 2013, 80, 1385–1392. [CrossRef][PubMed]

31. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; et al. The Diagnosis of Dementia Due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease-Alzheimer’s & Dementia: The Journal of the Alzheimer’s Associa. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312027/ (accessed on 1 May 2019).

32. de Oliveira, M.O.; Nittrini, R.; Yassuda, M.S.; Brucki, S.M.D. Vocabulary Is an Appropriate Measure of Premorbid Intelligence in a Sample with Heterogeneous Educational Level in Brazil. Available online: https://www.hindawi.com/journals/bn/2014/875960/ (accessed on 29 May 2018).

33. Yamada, S.; Ishikawa, M.; Miyajima, M.; Atsushi, M.; Kimura, T.; Kazui, H.; Mori, E.; SINPHONI-2 Investigators (Appendix). Disease Duration: The Key to Accurate CSF Tap Test in INPH. *Acta. Neurol. Scand.* 2017, 135, 189–196. [CrossRef]

34. Guralnik, J.M.; Simonsick, E.M.; Ferrucci, L.; Glynn, R.J.; Berkman, L.F.; Blazer, D.G.; Scherr, P.A.; Wallace, R.B. A Short Physical Performance Battery Assessing Lower Extremity Function: Association With Self-Reported Disability and Prediction of Mortality and Nursing Home Admission. *J. Gerontol.* 1994, 49, M85–M94. [CrossRef]

35. Magni, E.; Binetti, G.; Bianchetti, A.; Rozzini, R.; Trabucchi, M. Mini-Mental State Examination: A Normative Study in Italian Elderly Population. *Eur. J. Neurol.* 1996, 3, 198–202. [CrossRef][PubMed]

36. Appollonio, I.; Leone, M.; Isella, V.; Piamarta, E.; Consoli, T.; Villa, M.L.; Forapani, E.; Russo, A.; Nichelli, P. The Frontal Assessment Battery (FAB): Normative Values in an Italian Population Sample. *Neural. Sci.* 2005, 26, 108–116. [CrossRef]

37. Giovagnoli, A.R.; Del Pesce, M.; Mascheroni, S.; Simoncelli, M.; Laiacona, M.; Capitani, E. Trail Making Test: Normative Values from 287 Normal Adult Controls. *Ital. J. Neurol. Sci.* 1984, 17, 305–309. [CrossRef]

38. Alcolea, D.; Pegueroles, J.; Muñoz, L.; Camacho, V.; López-Mora, D.; Fernández-León, A.; Bastard, N.L.; Huyck, E.; Nadal, A.; Olmedo, V.; et al. Agreement of Amyloid PET and CSF Biomarkers for Alzheimer’s Disease on Luminpe. *Ann. Clin. Transl. Neurol.* 2019, 6, 1815–1824. [CrossRef][PubMed]
39. Jack, C.R.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; et al. NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease. *Alzheimer’s Dement.* 2018, 14, 535–562. [CrossRef] [PubMed]

40. Manniche, C.; Hejl, A.-M.; Hasselbalch, S.G.; Simonsen, A.H. Cerebrospinal Fluid Biomarkers in Idiopathic Normal Pressure Hydrocephalus versus Alzheimer’s Disease and Subcortical Ischemic Vascular Disease: A Systematic Review. *J. Alzheimer’s Dis.* 2019, 68, 267–279. [CrossRef] [PubMed]

41. Taghdiri, F.; Gumus, M.; Algarni, M.; Fasano, A.; Tang-Wai, D.; Tartaglia, M.C. Association Between Cerebrospinal Fluid Biomarkers and Age-Related Brain Changes in Patients with Normal Pressure Hydrocephalus. *Sci. Rep.* 2020, 10, 9106. [CrossRef]

42. Tsai, A.; Malek-Ahmadi, M.; Kahlon, V.; Sabbagh, M.N. Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer’s Disease. *J. Alzheimer’s Dis. Parkinsonism* 2014, 4, 1000150. [CrossRef]

43. Abu-Rumeileh, S.; Giannini, G.; Polischi, B.; Albini-Riccioli, L.; Milletti, D.; Oppi, F.; Stanzani-Maserati, M.; Capellari, S.; Mantovani, P.; Palandrini, G.; et al. Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study. *J. Alzheimer’s Dis.* 2019, 68, 723–733. [CrossRef]

44. Kapaki, E.N.; Paraskevas, G.P.; Tzerakis, N.G.; Sfagos, C.; Seretis, A.; Kararizou, E.; Vassilopoulos, D. Cerebrospinal Fluid Tau, Phospho-Tau181 and Beta-Amyloid1-42 in Idiopathic Normal Pressure Hydrocephalus: A Discrimination from Alzheimer’s Disease. *Eur. J. Neurol.* 2007, 14, 168–173. [CrossRef] [PubMed]

45. Blennow, K. Cerebrospinal Fluid Protein Biomarkers for Alzheimer’s Disease. *NeuroRX* 2004, 1, 213–225. [CrossRef] [PubMed]

46. Lewczuk, P.; Ermann, N.; Andreasson, U.; Schultheis, C.; Podhorna, J.; Spitzer, P.; Maler, J.M.; Kornhuber, J.; Blennow, K.; Zetterberg, H. Plasma Neurofilament Light as a Potential Biomarker of Neurodegeneration in Alzheimer’s Disease. *Alzheimer’s Res. Ther.* 2018, 10, 71. [CrossRef]

47. Ray, B.; Reyes, P.F.; Lahiri, D.K. Biochemical Studies in Normal Pressure Hydrocephalus (NPH) Patients: Change in CSF Levels of Amyloid Precursor Protein (APP), Amyloid-Beta (Aβ) Peptide and Phospho-Tau. *J. Psychiatr. Res.* 2011, 45, 539–547. [CrossRef] [PubMed]

48. Baird, G.; Montine, T.J.; Chang, J.J.; Hu, S.-C.; Avellino, A.M. Cerebrospinal Fluid Total Tau Is Increased in Normal Pressure Hydrocephalus Patients Who Undergo Successful Lumbar Drain Trials. *Cureus* 2017, 9, e1265. [CrossRef]

49. Migliorati, K.; Panciani, P.P.; Pertichetti, M.; Borrini, B.; Archetti, S.; Padovani, A.; Terzi, L.; Bruscella, S.; Fontanella, M.M. P-Tau as Prognostic Marker in Long Term Follow up for Patients with Shunted INPH. *Neurol. Res.* 2021, 43, 78–85. [CrossRef]

50. Pyykkö, O.T.; Lumela, M.; Rummukainen, J.; Nerg, O.; Seppälä, T.T.; Herukka, S.-K.; Koivisto, A.M.; Alafuzoff, I.; Puli, L.; Savolainen, S.; et al. Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus. *PLoS ONE* 2014, 9, e91974. [CrossRef] [PubMed]

51. Giacomucci, G.; Mazzeo, S.; Bagnoli, S.; Casini, M.; Padiglioni, S.; Polito, C.; Berti, V.; Balestrini, J.; Ferrari, C.; Lombardi, G.; et al. Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia. *J. Pers. Med.* 2021, 11, 47. [CrossRef]

52. Lehmann, S.; Delaby, C.; Boursier, G.; Catteau, C.; Ginestet, N.; Tiers, L.; Maceski, A.; Navucet, S.; Paquet, C.; Dumurgier, J.; et al. Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. *Front. Aging Neurosci.* 2018, 10, 138. [CrossRef] [PubMed]